For instance, targeting B7-H3, an immune checkpoint molecule associated with poor prognosis in several cancers, has been shown to augment the antitumor response of cytotoxic lymphocytes when engaged by TCEs or chimeric antigen receptor (CAR) T cells [5, 6]. Here, CD276 is linked to cancer.